Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-26T09:17:03.564Z Has data issue: false hasContentIssue false
  • English
  • Français

The Treatment of Anxiety: Realistic Expectations and Risks Posed by Controlled Substances

Published online by Cambridge University Press:  01 January 2021

Robert L. DuPont  and
Caroline M. DuPont
Get access Rights & Permissions [Opens in a new window]

Extract

We can think about the use of controlled substances in the treatment of anxiety disorders in two simple but diametrically opposed ways. First, we can say that anxiety disorders are trivial and require only acts of willpower, or, if anxiety disorders do require treatment, they are better treated without the use of benzodiazepines (BZs). When BZs are used to treat anxiety, they pose grave risks of addiction to the patients to whom these medicines are prescribed; they relieve patients’ symptoms, but are the equivalent of a pharmacological “roach motel,” a haven into which many unsuspecting patients enter, but from which few emerge without becoming addicted. Patients must then face terrible struggles to free themselves of dependence on BZs, and this compounds the problem for which they sought treatment. Furthermore, the large number of prescriptions for BZs are a threat to the public health because these drugs are widely abused by alcoholics and drug addicts.

Type
Article
Information
Journal of Law, Medicine & Ethics , Volume 22 , Issue 3 , Fall 1994 , pp. 206 - 214
Copyright
Copyright © American Society of Law, Medicine and Ethics 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Shader, Richard I. Greenblatt, David J., “Use of Benzodiazepines in Anxiety Disorders,” New England Journal of Medicine, 328, no. 19 (1993): 1398–1405; and Brown, Candace S. Rakel, Robert E. Wells, Barbara G. Downs, John M. Akiskal, Hagop S., “A Practical Update on Anxiety Disorders and Their Pharmacologic Treatment,” Archives of Internal Medicine, 151 (1991): 873-84.Google Scholar
DuPont, Robert L., ed., Abuse of Benzodiazepines: The Problems and the Solutions, Supplement 1 to The American Journal of Drug and Alcohol Abuse, Volume 14, (New York: Marcel Dekker, 1988), pp. 1–70.Google Scholar
DuPont, Robert L. Saylor, Keith E., “Sedatives/Hypnotics and Benzodiazepines,” in Frances, R.J. Miller, S.I., eds., Clinical Textbook of Addictive Disorders (New York: Guilford Press, 1991), pp. 69–102.Google Scholar
The problem of the use of controlled substances in medical practice has recently been reviewed. See Wilford, Bonnie B., ed., Balancing the Response to Prescription Drug Abuse—Report of a National Symposium on Medicine and Public Policy (Chicago: American Medical Association, Department of Substance Abuse, 1990).Google Scholar
National Institute of Mental Health, “Epidemiologic Catchment Area (ECA) Program Community Surveys in Five Sites: St. Louis, MO; Baltimore, MD; New Haven, CT; Durham, NC; and Los Angeles, CA 1980–1985.” Public use tapes.Google Scholar
DuPont, Robert L. Rice, Dorothy P. Miller, Leonard S. Shiraki, Sarah S. Rowland, Clayton R. Harwood, Henrick J., “The Economic Costs of Anxiety Disorders,” paper presented at a seminar at the National Institutes of Health, Bethesda, Maryland, February 2, 1993, and at the Anxiety Disorders Association of America annual meeting, Charleston, South Carolina, March 19, 1993.Google Scholar
Ballenger, James C., “Panic Disorder: Efficacy of Current Treatments,” in Health Care Reform for Americans with Severe Mental Illnesses: Report of the National Advisory Mental Health Council (Rockville: U.S. Department of Health and Human Services, Public Health Service, National Advisory Mental Health Council, 1993), pp. 88–106; Jenike, Michael A., “Obsessive-Compulsive Disorder: Efficacy of Specific Treatments as Assessed by Controlled Trials,” in Health Care Reform for Americans with Severe Mental Illnesses: Report of the National Advisory Mental Health Council (Rockville: U.S. Department of Health and Human Services, Public Health Service, National Advisory Mental Health Council, 1993), pp. 107-30; American Psychiatric Association, “Anxiety Disorders,” Section 18 in Treatments of Psychiatric Disorders: A Task Force Report of the American Psychiatric Association (Washington, D.C.: American Psychiatric Association, Vol. 3, 1989), pp. 2007-92; and Noyes, R. Roth, M. Burrows, G.D., eds., Handbook of Anxiety, Volume 4: The Treatment of Anxiety (Amsterdam: Elsevier, 1990).Google Scholar
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (Washington, D.C.: American Psychiatric Association, 4th ed., 1994).Google Scholar
Jaffe, Jerome H., “Drug Addiction and Drug Abuse,” in Gilman, A.G. Rall, T.W. Nies, A.S. Taylor, P., eds., The Pharmacological Basis of Therapeutics (New York: Pergamon Press, 8th ed., 1990), pp. 522–73; and Griffiths, Roland R. Sannerud, C.A., “Abuse of and Dependence on Benzodiazepines and Other Anxiolytic/Sedative Drugs,” in Meltzer, H.Y., ed., Psychopharmacology: The Third Generation of Progress (New York: Raven Press, 1987), pp. 1535-41.Google Scholar
Sellers, Edward M. Ciraulo, Domenic A. DuPont, Robert L. Griffiths, Roland R. Kosten, Thomas R. Romach, Myroslava K. Woody, George E., “Alprazolam and Benzodiazepine Dependence,” submitted to the Journal of Clinical Psychiatry; and see DuPont, , supra note 2.Google Scholar
DuPont, Robert L., “Aiming Straight: Benzodiazepines, Addiction, and Public Policy,” New Jersey Medicine, 90, no. 11 (1993): 823–26; and Tracy Orleans, C. Slade, John, eds., Nicotine Addiction: Principles and Management (New York: Oxford Press, 1993).Google Scholar
DuPont, Robert L., The Selfish Brain: Learning From Addiction (Washington, D.C.: American Psychiatric Press, forthcoming).Google Scholar
DuPont, Robert L., “Benzodiazepines and Chemical Dependence: Clinical Guidelines,” in Practical Clinical Management: Drug Abuse Education for the Primary Care Physician (Baltimore: Medical and Chirurgical Faculty of Maryland, 1990), pp. 53–59.Google Scholar
Wheatley, David, ed., The Anxiolytic Jungle: Where Next? (Chichester, West Sussex: John Wiley & Sons, 1990).Google Scholar
Rosenbaum, Jerrold, ed., “Long-Term Treatment of Mood and Anxiety Disorders,” Psychiatric Annals, 24, no. 6 (1994); DuPont, Robert L., “Choosing the Right Treatment for the Patient with Anxiety,” Modem Medicine, 60, no. 4 (1992): 64–76; and see American Psychiatric Association, supra note 7.Google Scholar
Saylor, Keith E. DuPont, Robert L. Brouillard, Mary, “Self-Help Treatment of Anxiety Disorders,” in Noyes, R. Roth, M. Burrows, G.D., eds., Handbook of Anxiety, Volume 4: The Treatment of Anxiety (Amsterdam: Elsevier, 1990), pp. 483–96.Google Scholar
Ballenger, James C. Burrows, Graham D. DuPont, Robert L. Lesser, Ira M. Noyes, Russell Pecknold, John C. Rifkin, Arthur Swinson, Richard P., “Alprazolam in Panic Disorder and Agoraphobia: Results from a Multicenter Trial—I. Efficacy in Short-Term Treatment,” Archives of General Psychiatry, 45 (1988): 413–22.CrossRefGoogle Scholar
These issues, including the controversies about the use of BZs, have been recently explored. See Smith, David E. Wesson, Donald R., The Benzodiazepines—Current Standards for Medical Practice (Lancaster: MTP Press, 1985); Roy-Byrne, Peter P. Cowley, Deborah S., eds., Benzodiazepines in Clinical Practice: Risks and Benefits (Washington, D.C.: American Psychiatric Press, 1991); and American Psychiatric Association, Treatments of Psychiatric Disorders: A Task Force Report of the American Psychiatric Association (Washington, D.C.: American Psychiatric Association, Vol. 3, 1989).CrossRefGoogle Scholar
Sheehan, David V. Raj, Ashok, “Benzodiazepine Treatment of Panic Disorder,” in Noyes, R. Roth, M. Burrows, G.D., eds., Handbook of Anxiety, Volume 4: The Treatment of Anxiety (Amsterdam: Elsevier, 1990), pp. 169–206; and Zorumski, Charles F. Isenberg, Keith E., “Insights into the Structure and Function of GABA-Benzodiazepine Receptors: Ion Channels and Psychiatry,” American Journal of Psychiatry, 148, no. 2 (1991): 162-71.Google Scholar
DuPont, Robert L. Swinson, Richard P. Ballenger, James C. Burrows, Graham D. Noyes, Russell Rubin, Robert T. Rifkin, Arthur Pecknold, John C., “Discontinuation of Alprazolam after Long-Term Treatment of Panic Related Disorders,” Journal of Clinical Psychopharmacology, 12, no. 5 (1992): 352–54.CrossRefGoogle Scholar
Busto, Usoa E. Sellers, Edward M. Naranjo, C.A. Cappell, H. Sanchez-Craig, M. Sykora, K., “Withdrawal Reaction After Long-Term Therapeutic Use of Benzodiazepines,” New England Journal of Medicine, 315 (1986): 854–59; and see DuPont, et al., supra note 20.CrossRefGoogle Scholar
Pecknold, John C. Swinson, Richard P. Kuch, Klaus Lewis, Carl P., “Alprazolam in Panic Disorder and Agoraphobia: Results from a Multicenter Trial—III. Discontinuation Effects,” Archives of General Psychiatry 45 (1988): 429–36; see American Psychiatric Association, supra note 18; and see Busto, et al., supra note 21.CrossRefGoogle Scholar
See DuPont, , supra note 15.Google Scholar
DuPont, Robert L., Use of Benzodiazepines: Risks and Benefits (Rockville: DuPont Associates, P.A., 1989); and DuPont, Robert L., Getting Off Benzodiazepines: A Patient's Guide (Rockville: DuPont Associates, P.A., 1990).Google Scholar
DuPont, Robert L. McGovern, John P., A Bridge to Recovery—An Introduction to 12-Step Programs (Washington, D.C.: American Psychiatric Press, 1994).Google Scholar
Al-Non Family Group Headquarters, Al-Non Faces Alcoholism (New York: Al-Non Family Group Headquarters, Inc., 1990).Google Scholar
Dilsaver, Steven C. Greden, J.F., “Antidepressant Withdrawal Phenomena: A Review,” Biological Psychiatry, 19 (1984): 237–56.Google Scholar
See DuPont, et al., supra note 20.Google Scholar
See American Psychiatric Association, supra note 18.Google Scholar
Ciraulo, Domenic A. Sands, Brian F. Shader, Richard I., “Alcoholics' Use of Benzodiazepines,” American Journal of Psychiatry, 146, no. 5 (1989): 683–84.CrossRefGoogle Scholar
Hollander, Eric Hatterer, Julie Klein, Donald F., “Antidepressants for the Treatment of Panic and Agoraphobia,” in Noyes, R. Roth, M. Burrows, G.D., eds., Handbook of Anxiety, Volume A: The Treatment of Anxiety (Amsterdam: Elsevier, 1990), pp. 207–31.Google Scholar
Stone, Michael H., “Psychotherapy for the Treatment of Anxiety Disorders,” in Noyes, R. Roth, M. Burrows, G.D., eds., Handbook of Anxiety, Volume 4: The Treatment of Anxiety (Amsterdam: Elsevier, 1990), pp. 389–404.Google Scholar
See DuPont, , supra note 12.Google Scholar
DuPont, Robert L., “Thinking About Stopping Treatment for Panic Disorder,” Journal of Clinical Psychiatry, 51, no. 12, supp. A (1990): 38–45; and see Jaffe, , supra note 9.Google Scholar
See DuPont, , supra note 11; and see DuPont, , supra note 12.Google Scholar
DuPont, Robert L., Benzodiazepines: The Social Issues (Rockville: Institute for Behavior and Health, 1986); DuPont, Robert L. Saylor, Keith E., “Depressant Substances in Adolescent Medicine,” Pediatrics in Review, 13, no. 10 (1992): 381-86; see DuPont, , supra note 11, at 825; and see DuPont, , supra note 15, at 66.Google Scholar
Miller, Norman S., ed., Treating Coexisting Psychiatric and Addictive Disorders: A Practical Guide (Center City, MN: Hazelden Publishing, 1994).Google Scholar
DuPont, Robert L., “The Twelve Step Approach,” in Miller, Norman S., ed., Treating Coexisting Psychiatric and Addictive Disorders: A Practical Guide (Center City, MN: Hazelden Publishing, 1994), pp. 177–97.Google Scholar
Id.Google Scholar
DuPont, Robert L., “Anxiety and the BZs,” ADAA Reporter, IV, no. 3 (1993): 1.Google Scholar
Pollack, Mark H. Otto, Michael W., “Long-Term Pharmacologic Treatment of Panic Disorder,” Psychiatric Annals, 24, no. 6 (1994): 291–98.CrossRefGoogle Scholar
Klerman, Gerald L. Weissman, Myrna M., “The Course, Morbidity, and Costs of Depression,” Archives of General Psychiatry, 49 (1992): 831–34.CrossRefGoogle Scholar
DuPont, Robert L., “Policy Concerns: Addiction, Anxiety and Benzodiazepines: A Public Policy Perspective,” in Wilford, Bonnie B., ed., Balancing the Response to Prescription Drug Abuse—Report of a National Symposium on Medicine and Public Policy (Chicago: American Medical Association, Department of Substance Abuse, 1990), pp. 109–17; see DuPont, , supra note 11; and see DuPont, , supra note 13.Google Scholar